Dr. Randall Bateman is a leading neurologist and scientist at the Washington University School of Medicine in St. Louis, who studies the hereditary and rare form of Alzheimer's disease, early onset familial Alzheimer's disease (also known as dominantly inherited Alzheimer's disease). Dr. Bateman is the Charles F. and Joanne Knight Distinguished Professor of Neurology and Director of Dominantly Inherited Alzheimer's Network (DIAN) and DIAN-TU, an international research effort that coordinates clinical trials to study and deliver potential therapies to the early onset familial Alzheimer's disease community. The perfect guest to answer all our questions about inherited Alzheimer's disease, where the field currently is, and where it's going.

 

 

In this video, Dr. Bateman answers our questions about clinical trials and research participation for early onset familial Alzheimer's disease patients. These questions include: How data from DIAN clinical trials is shared with the AD research community? An explanation of DIAN’s new brain donation program. Recommended ways that participants can work with researchers to create new scientific knowledge and advance the fight against AD? How the discovery of the protective Christchurch mutation affects the development of new therapies? How the FDA decision on aducanumab will affect DIAN clinical trials and drugs? What efforts DIAN and the AD field are taking to increase diversity and inclusion in clinical trials?

 

For more information on Dr. Bateman's research.

For more information about DIAN.